baber/WOPTO huggingface dataset:
Patent JP-H0222130-B2 (JP)
IPC: C22C9/00
Filed: 1985-11-26
Abstract: PURPOSE:To improve the heat resistance, rupture strength and bonding characteristics by adding a very small amount of one or more among Cd, Pb and Ti to pure Cu having a regulated S content. CONSTITUTION:A bonding wire for a semiconductor device is made of a material obtd. by adding <=0.02% one or more among Cd, Pb and Ti to Cu having >=99.999% purity and <=0.0005wt% S content. By this composition, the bonding wire has bonding characteristics comparable to those of a fine pure gold wire and also has superior heat resistance and rupture strength, so it is applicable to high-speed automatic bonding.
Patent JP-2941406-B2 (JP)
IPC: C08F8/30
Filed: 1990-10-25
Granted: 1999-08-25
Abstract: Vinyl unsaturated copolymers are described which are obtained in a two-step process and which consist of monomeric units A, B, C, D and E, copolymerized in a first step, and in a second step reacted with a reactive vinyl monomer Mv, and in which A is a silicon or fluorine containing vinyl monomer, 20-79.5% by weight; B is N,N-dimethylacrylamide, N-vinylpyrrolidone, or N-vinylacetamide, 20-79.5% by weight; C is an active hydrogen containing vinyl monomer, 0.5-25% by weight; D are other copolymerizable comonomers, 0-30% by weight, and E is a chain transfer agent, 0-10 mol percent. Mv is a vinyl unsaturated isocyanate. These vinyl unsaturated polymers are useful, either by themselves or in combination with other copolymerizable vinyl monomers, as heat or UV-curable coatings or glass, plastic, wood, paper, textiles, metal or ceramics, said coatings possessing low surface energies and low refractive indices. They are especially useful as UV-curable hydrophilic coatings and water-swelling biocompatible polymers, especially fully molded highly oxygen-permeable contact lenses.
Patent JP-3199648-B2 (JP)
IPC: G10L25/93
Filed: 1996-10-30
Granted: 2001-08-20
Abstract: A reset signal generating part outputs reset signals RV and RD to a signal discriminating part, based on an output from a 2100 Hz detecting part which detects whether or not a tone of 2100 Hz exists in an input signal. When the 2100 Hz tone is detected, the signal discriminating part firstly resets a discrimination state at "speech" and secondly sets the discrimination state at "data" based on the reset signal. Therefore, a signal discrimination apparatus, wherein it is possible to reset the discrimination state at "speech" at the beginning of a facsimile call even when no call control information is received, can be provided.
Patent JP-3180735-B2 (JP)
IPC: H04W56/00
Filed: 1997-10-22
Granted: 2001-06-25
Abstract: A radio terminal comprises an antenna for receiving a reception band signal and outputting a transmission band signal, a duplexer which is coupled with the antenna to use the antenna both for transmission of the transmission band signal and reception of the reception band signal, a transmitter section for converting a transmission signal into the transmission band signal,and outputting the transmission band signal to the antenna through the duplexer, and a receiver section for converting the reception band signal transmitted from the antenna through the duplexer into a demodulated signal. The radio terminal further comprises a reference signal generating section for generating a reference signal, a selector for providing the transmitter section with the reference signal in a first time to transmit the reference signal through the transmitter section, the duplexer and the receiver section and providing the transmitter section with the transmission signal in a second time after the first time, and a delay time measuring section for measuring a total internal delay time from the generation of the reference signal to the returning of the reference signal to the receiver section to adjust a transmit timing of the transmission band signal transmitted from the antenna in accordance with the total internal delay time. <IMAGE>
Patent JP-3948138-B2 (JP)
IPC: B60L50/16
Filed: 1998-10-20
Granted: 2007-07-25
Abstract: PROBLEM TO BE SOLVED: To suppress shocks given to a vehicle, when a drive state is switched to a driven state, and vice versa. SOLUTION: A motor generator is arranged in the power transmitting route between an engine and wheels, and a regenerative braking power controller can switch a drive state, in which a vehicle is run with the power outputted from at least either one of the engine and motor generator, to a driven state in which the power inputted from the wheel side is transmitted to the power transmitting route, and vice versa, and can generate regenerating braking power by driving the motor generator with the power inputted from the wheel side.  The controller is provided with an acceleration demand discriminating means (steps 203 and 208), which discriminates the increasing degree of acceleration demand, when the controller switches the driven state to the driving state and a motor generator control means (steps 209 and 210), which controls the regenerative braking power when the driven state is switched to the drive state, according to the increasing degree of the acceleration demand.
Patent JP-3872188-B2 (JP)
IPC: B05B15/65
Filed: 1997-11-06
Granted: 2007-01-24
Abstract: The spray head (2) is coupled to the supply lines and to the mounting (4) in a simple twist lock action. The underside of the spray head has a pivot which engages a pivot coupling (6) on the mounting. The head is twisted on the mounting until the rear end is secured by a sprung grip (34). The release is obtained using a similar action. The connecting ducts for the spray head connect with their corresponding ducts in the mounting when the head is secured into place. The spray head is mounted in its holder without any external connections being required.
Patent JP-3963490-B2 (JP)
IPC: C07D401/04
Filed: 1994-12-05
Granted: 2007-08-22
Abstract: The present invention relates to a one-pot process for the preparation of 7-heterocyclyl-substituted 3-quinolonecarboxylic acid derivatives. They have a strong antimicrobial action and include active compounds such as ofloxacin, ciprofloxacin or enrofloxacin.
Patent JP-3114997-B2 (JP)
IPC: H01L21/288
Filed: 1994-06-07
Granted: 2000-12-04
Abstract: PCT No. PCT/IB94/00147 Sec. 371 Date Feb. 3, 1995 Sec. 102(e) Date Feb. 3, 1995 PCT Filed Jun. 7, 1994 PCT Pub. No. WO94/29904 PCT Pub. Date Dec. 22, 1994.A method of making the compound CuInSe2 (CIS) by depositing a precursor of the compound at least partly electrolytically on a substrate and forming CuInSe2 by thermal reaction.
Patent JP-4184447-B2 (JP)
IPC: F16K31/53
Filed: 1998-06-05
Granted: 2008-11-19
Abstract: Valves are disclosed including a housing having at least one fluid inlet and at least one fluid outlet, a valve seat for at least one of the fluid inlets and fluid outlets, a diaphragm movable between a first position engaged with the valve seat and a second position disengaged from the valve seat, the diaphragm having a surface area which is greater than the size of the valve seat so that the surface area of the diaphragm is greater than the surface area necessary for abutment against the valve seat, an actuator for actuating the diaphragm between the first and second positions, and an activator for displacing the diaphragm whereby at least partially portions of the surface area of the diaphragm are exposed to the valve seat upon displacement of the diaphragm.
Patent JP-H0456659-B2 (JP)
IPC: A61K9/14
Filed: 1984-06-22
Abstract: The present invention is concerned with the formation of small particles of organic compounds whose solubility in water is independent of temperature and greater at a first pH than at a second pH. upon precipitation by pH change with or without a change in temperature, but in the presence of a surfactant mixture.
Patent JP-3195363-B2 (JP)
IPC: A61P9/10
Filed: 1996-05-29
Granted: 2001-08-06
Abstract: Methods for inhibiting intimal hyperplasia in the vasculature of mammals, including primates, are disclosed. The methods comprise administering to the mammal a non-peptide PDGF antagonist such as 4-(2-(N-(2-carboxamidoindole)aminoethyl)-benzenesulfonamides or sulfonylureas. The methods are useful in reducing intimal hyperplasia due to, for example, vascular injuries resulting from angioplasty, endarterectomy, reduction atherectomy or anastomosis of a vascular graft. The non-peptide PDGF antagonists may optionally be administered coordinately with heparin, whereby the coordinately administered of non-peptide PDGF antagonist and heparin are combinatorially effective in inhibiting intimal hyperplasia.
Patent JP-3877007-B2 (JP)
IPC: A63C9/00
Filed: 1996-08-07
Granted: 2007-02-07
Abstract: PCT No. PCT/AT96/00142 Sec. 371 Date May 5, 1997 Sec. 102(e) Date May 5, 1997 PCT Filed Aug. 7, 1996 PCT Pub. No. WO97/06864 PCT Pub. Date Feb. 27, 1997There is disclosed a sliding device, in particular a ski (1), having a carrying structure (1') as well as a core (11) at least substantially rigidly connected therewith, and a binding carrier arranged above the core (11) in the longitudinal middle portion of the sliding device and extending at least over the binding area in the longitudinal direction of the sliding device, the binding carrier being elastically supported relative to the carrying structure and the core (11) so as to avoid a transmission of oscillations and impacts from the ski (1) to the ski binding; to increase the stiffness and for an improved introduction of forces, the binding carrier is designed as a deflection-resistant shell carrier (2; 2'; 2'') which also laterally embraces the core (11). (FIG. 4)
Patent JP-2728134-B2 (JP)
IPC: A61K31/401
Filed: 1988-10-28
Granted: 1998-03-18
Abstract: The invention relates to a composition for therapeutic, especially postoperative and posttraumatic, parenteral nutritional support treatment, which composition is based on a conventional amino acid mixture, the composition being characterised in that it also includes L- glutamine and/or alpha-ketoglutarate and optionally L- asparagine, the components of the composition, expressed in g dry component/l aqueous solution, being: glycine (1-12), aspartate (1-10), glutamate (2-12), alanine (2-20), arginine (2-14), cysteine/cystine (0.4-2.0), histidine (2-8), isoleucine (2-8), leucine (2-8), lysine (2-12), methionine (1-6), phenylalanine (4-10), proline (4-10), serine (2-10), threonine (2-8), tryptophan (1-3), tyrosine (0.2-1), valine (2-8), and additionally 5-30 g/l L-glutamine and/or 5-25 g/l alpha-ketoglutarate, and optionally 0.5-10 g/l L-asparagine and/or acetoacetate, or salts or esters thereof. The invention also relates to the use of L-glutamine and/or its derivative alpha-ketoglutarate, and optionally L-asparagine and/or its derivative acetoacetate for the preparation of a composition intended for therapeutic, especially postoperative and posttraumic, parenteral nutritional support treatment, which use is characterised in that L-glutamine and/or alpha-ketoglutarate and optionally L-asparagine and/or acetoacetate, dissolved in water and sterile-filtered, are added in cold-stored and freeze-dried form or other sterile powder form to a commercial amino acid nutrient solution immediately before the therapeutic treatment.
Patent JP-3940166-B2 (JP)
IPC: B26B21/44
Filed: 1995-07-07
Granted: 2007-07-04
Abstract: This invention pertains to therapeutic wound healing compositions useful for preventing and reducing injury to mammalian cells affixed to razor cartridges to form therapeutic razor cartridges with wound healing compositions. In one embodiment of this invention the therapeutic wound healing composition comprises (a) pyruvate; (b) an antioxidant; and (c) a mixture of saturated and unsaturated fatty acids. This invention also pertains to methods for making and using the razor cartridges comprising therapeutic wound healing compositions.
Patent JP-2712056-B2 (JP)
IPC: C08F20/34
Filed: 1993-01-11
Granted: 1998-02-10
Abstract: A non-crosslinked anion exchange resin consisting of structural units represented by the general formula (I): <CHEM> wherein R1 represents a benzyl group or an alkyl group having 1 to 20 carbon atoms, R2 and R3 may be identical or different and each represent a lower alkyl group having 1 to 4 carbon atoms, R4 represents a hydrogen atom or a lower alkyl group, X represents a physiologically acceptable counter ion, n is an integer of from 1 to 3, and p is an average degree of polymerization ranging from 10 to 10,000; and a pharmaceutical composition comprising said non-crosslinked anion exchange resin. <IMAGE>
Patent JP-3035342-B2 (JP)
IPC: A23L29/269
Filed: 1990-08-16
Granted: 2000-04-24
Abstract: Substantially fat-free cheese slice products and methods for manufacturing such products, comprising less than about 1.67 weight percent fat.
Patent JP-4387458-B2 (JP)
IPC: C12N1/15
Filed: 1996-10-07
Granted: 2009-12-16
Abstract: Specific binding members comprising human antibody antigen binding domains specific for human transforming growth factor beta (TGF beta ) bind specifically isoforms TGF beta 2 and TGF beta 1 or both, preferentially compared with TGF beta 3. Specific binding members may be isolated and utilised in the treatment of disease, particularly fibrotic disease and also immune/inflammatory diseases. Therapeutic utility is demonstrated using in vitro and in vivo models. Full sequence and binding information is provided, including epitope sequence information for a particularly advantageous specific binding member which binds the active form of TGF beta 2, neutralising its activity, but does not bind the latent form.
Patent JP-3263076-B2 (JP)
IPC: C07H15/26
Filed: 1993-03-16
Granted: 2002-03-04
Abstract: Avermectin compounds are glycosylated at the 4',13- Or 14a-positions by adding the avermectin compounds to the fermentation medium of a novel strain of Streptomyces avermitilis. The 4'-hydroxy, 13-hydroxy and 14a-hydroxy methyl groups of the avermectin compound are glycosylated with a glycosyl moiety, specifically an oleandrose group. The new strain offers the added advantage of not producing any C5-O-methylation products. The compounds are potent anthelmintic and antiparasite agents, and compositions for such uses are also disclosed. U.S patent 3950360 to Aoki e &cir& _t &cir& _ a &cir& _1 &cir& _, discloses milbemycin compounds and European patent application 242052 to Rudd e &cir& _t &cir& _ a &cir& _1 &cir& _ discloses nemedectin compounds with a 25-hydroxy group and a 25-unsaturated alkyl group.
Patent JP-3286976-B2 (JP)
IPC: C08K13/02
Filed: 1991-09-27
Granted: 2002-05-27
Abstract: A flame retardant epoxy molding compound comprises an epoxy, a hardener preferably of the novolac or anhydride type, a catalyst, a mold release agent, preferably a filler, preferably a colorant, preferably a coupling agent, an organic compound containing a higher percent of halogen (which can be part of the resin or the hardener), preferably the meta-brominated cresol epoxy novolac type, preferably containing at least about 0.5% of bromine by weight of the molding compound, a lower percent of sodium, preferably in the range of 0.03-0.06% by weight of the antimony pentoxide, a lower percent of antimony pentoxide, preferably in the range of from less than about 0.8% by weight of the molding compound, and an amount of magnesium aluminum carbonate hydrate less than or about 4.0% by weight of the molding compound. The flame retardant epoxy compounds when used to encapsulated the semiconductor devices have improved high temperature stability and reliability compared to similar prior art molding compounds.
Patent JP-2955778-B2 (JP)
IPC: C22C19/00
Filed: 1991-08-08
Granted: 1999-10-04
Abstract: A precipitation strengthenable, nickel-cobalt-iron base alloy and articles made therefrom are disclosed. The alloy contains controlled amounts of silicon, nickel, cobalt, iron, chromium, niobium, titanium, and aluminum which are critically balanced to provide a unique combination of high strength, good ductility, and controlled thermal expansion, together with good thermal stability and good oxidation resistance up to about 1200 degrees F. or higher.
Patent JP-4278181-B2 (JP)
IPC: G01N33/22
Filed: 1997-10-28
Granted: 2009-06-10
Abstract: Method for controlling movement of a liquid from a first location to a second location via a dispenser for the liquid located in a liquid line between the first and second location. The dispenser includes a nozzle, an internal liquid conduit, a valve, a body portion, a hollow annular collar and a first detector. The first detector is located in the collar which is positioned around the nozzle or between the nozzle and the body portion such that the first detector is in vapor communication with a vapor space above the second location. The vapor from the vapor space is analyzed by withdrawing the vapor past the first detector and using the results of the analysis to control the operation of the valve.
Patent JP-3535521-B2 (JP)
IPC: A61K48/00
Filed: 1997-01-23
Granted: 2004-06-07
Abstract: DNA sequences for creating replication defective retroviral vector producer cells either in vivo, or in vitro for reimplantation. The retroviral vector comprises at least one heterologous gene and functional env and gag-pol genes are absent from the vector so that retrovirus structural proteins are not expressed by the target cells infected and transduced by the vector.
Patent JP-4504463-B2 (JP)
IPC: C12N15/12
Filed: 1996-04-29
Granted: 2010-07-14
Abstract: The present invention describes the identification, isolation, sequencing and characterization of two human presenilin genes, PS-1 and PS-2, mutations which lead to Familial Alzheimer's Disease. Also identified are presenilin gene homologues in mice,  C. elegans  and  D. melanogaster.  Nucleic acids and proteins comprising or derived from the presenilins are useful in screening and diagnosing Alzheimer's Disease, in identifying and developing therapeutics for treatment of Alzheimer's Disease, and in producing cell lines and transgenic animals useful as models of Alzheimer's Disease.
Patent JP-4024859-B2 (JP)
IPC: H04B15/00
Filed: 1997-04-15
Granted: 2007-12-19
Abstract: A system and method for reducing radio frequency interference arising in connection with pulsed transmission over time division multiplexed communication channels. In a first embodiment, a subscriber station is nominally assigned all of the slots of each frame of a first transmit channel. By transmitting RF energy substantially continuously, the subscriber station reduces interference arising from pulsed transmission. In a second embodiment, a subscriber station is nominally assigned one or more slots of each frame of a primary channel for conventional transmission of useful information, and is also instructed to continuously transmit RF energy over an auxiliary channel at times other than during the assigned primary channel slots. In this way, interference generated in the vicinity of the subscriber station is reduced due to the substantially continuous transmission of RF energy by the subscriber station. More than one subscriber station may simultaneously utilize the auxiliary channel during reduced interference mode operation.
Patent JP-4065571-B2 (JP)
IPC: A61Q17/04
Filed: 1998-02-27
Granted: 2008-03-26
Abstract: The invention relates to an active ingredient combination containing erythrulose and a further reducing sugar with self-tanning properties, for example, dihydroxyacetone, which combination is used for artificially tanning the skin. Compared with compounds containing, for example, only dihydroxyacetone, said active ingredient combination and cosmetic compounds based thereon result in an even and longer-lasting colouring of the skin and prevent skin dehydration and uneven flaking.
Patent ES-2178978-B2 (ES)
Title: Unidad de control de la potencia electrica para un motor de ventilador.
Inventor: WOLF JEAN
IPC: F04D27/02
Filed: 2001-12-18
Granted: 2005-05-01
Abstract: Unidad de control de la potencia eléctrica para un motor de ventilador que presenta una disposición (R1, R2, R3) de resistencias eléctricas insertadas en el circuito eléctrico de un motor de ventilador. Según la invención, en el circuito eléctrico del motor de ventilador se encuentra insertado un elemento PPTC (1) como protección contra el sobrecalentamiento que se halla en el recorrido del flujo (S) del medio producido por el motor de ventilador y está sometido al efecto refrigerante del flujo del medio. Es de aplicación por ejemplo, en motores de ventilador de instalaciones de climatización para automóviles.
Patent ES-2345085-B2 (ES)
Title: Cubierta solar de un edificio.
Inventor: KLAINSEK ZIZMOND JUAN C
IPC: F24J2/54
Filed: 2009-01-12
Granted: 2011-11-15
Abstract: Cubierta solar de un edificio, que se
caracteriza por ser una cubierta (1) diseñada con forma cuadrada,
rectangular o poligonal, que es capaz de balancearse por su
baricentro o punto central de equilibrio, gracias a los esfuerzos
aplicados en un mínimo de tres o más puntos (9), claramente
distanciados entre sí y entre su punto central de apoyo, logrando
evitar salirse de su perímetro en posición horizontal.
Patent ES-2460391-B2 (ES)
Title: Uso de L-Carnitina para proteger a los peces de la intoxicación por cilindrospermopsina
Inventor: CAMEAN FERNANDEZ ANA MARÍA
IPC: A23K50/80
Filed: 2012-11-08
Granted: 2014-10-06
Abstract: La presente invención se refiere al uso de una composición que comprende L-Camitina (LC) para el tratamiento, prevención y/o recuperación de efectos tóxicos en peces expuestos a Cilindrospermopsina (CYN). También se refiere al uso de la citada composición en la recuperación de las alteraciones histopatológicas producidas en los tejidos de la lista que comprende hígado, riñón, corazón, branquias y/o tracto gastrointestinal. Además, dicha composición se utiliza para la fabricación de un alimento funcional, un complemento vitamínico, o un complemento nutricional.
Patent AU-2001248416-B2 (AU)
Title: Valve assembly with or without integrated reducer for pressurised gas container
Inventor: PISOT PHILIPPE
IPC: F17C5/00
Filed: 2001-03-23
Granted: 2004-09-16
Abstract: The invention concerns a valve assembly or an on-off pressure reducer device for a pressurised gas container designed to co-operate with a conditioning connection for filling said container. The valve assembly or on-off pressure reducer comprises a filler connection (14) with a longitudinal axis, a guide end (18), and a thread (22) axially offset relative to said end. The end (18) has a periphery (20) provided with at least an impression (40) protruding outside the periphery, projecting in a plane orthogonal to said longitudinal axis, the impression (40) of said connection end being secant to a circle centred on said axis and whereof the diameter is equal to the smaller of the internal and external diameters of said thread.
Patent AU-2001261103-B2 (AU)
Title: Diagnostics and therapeutics for macular degeneration-related disorders
Inventor: MULLINS ROBERT F
IPC: C12Q1/6883
Filed: 2001-04-30
Granted: 2007-08-23
Abstract: The invention relates to methods for treating, preventing and diagnosing macular degeneration-related disorders.
Patent AU-2002218906-B2 (AU)
Title: Self-replicating RNA molecule from hepatitis C virus
Inventor: KUKOLJ GEORGE
IPC: C12Q1/6897
Filed: 2001-12-20
Granted: 2006-08-03
Abstract: A unique HCV RNA molecule is provided having an enhanced efficiency of establishing cell culture replication. Novel adaptive mutations have been identified within the HCV non-structural region that improves the efficiency of establishing persistently replicating HCV RNA in cell culture. This self-replicating polynucleotide molecule contains, contrary to all previous reports, a 5′-NTR that can be either an A as an alternative to the G already disclosed and therefore provides an alternative to existing systems comprising a self-replicating HCV RNA molecule. The G→A mutation gives rise to HCV RNA molecules that, in conjunction with mutations in the HCV non-structural region, such as the G(2042)C/R mutations, possess greater efficiency of transduction and/or replication. These RNA molecules when transfected in a cell line are useful for evaluating potential inhibitors of HCV replication.